Linvoseltamab-gcpt (Lynozyfic) coverage
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.743 alerts
Get alerted when Policy CP.PHAR.743 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed or refractory multiple myeloma in adults, and approval durations across lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Linvoseltamab-gcpt (Lynozyfic)
inv-01: Initial Therapy — Multiple Myeloma — Covered when ALL of the following are met:
Covered when ALL of the following are met:
Prescribed regimen must be FDA-approved or recommended by NCCN
inv-02: Continued Therapy — Multiple Myeloma — Continued coverage when ALL of the following are met:
Continued coverage when ALL of the following are met:
Prescribed regimen must be FDA-approved or recommended by NCCN
inv-03: Initial and Maintenance Dosing — Covered when dosing and scheduling align with the FDA-approved regimen for MM:
Covered when dosing and scheduling align with the FDA-approved regimen for MM:
Includes step-up doses and maintenance schedule per product labeling
Non–FDA approved indications not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with applicable off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (Health Insurance Marketplace/ICHRA), or CP.PMN.53 (Medicaid), or unless evidence of coverage documents permit the use.
The pivotal LINKER‑MM1 trial excluded patients with central nervous system involvement; specifically, patients with multiple myeloma with brain lesions or meningeal involvement were not enrolled and are an exclusion in the trial population.
Inclusion of a billing code in this policy is informational only; coding inclusion does not guarantee coverage. Coverage determinations remain subject to plan‑specific medical necessity rules and benefit language, and providers should follow the payer’s medical necessity and claims submission requirements.
Initial Therapy — Authorization and Dosing Requirements
inv-24: Initial therapy — initial approval criteria and dosing limits.
Initial approval criteria and dosing limits
Prescribed regimen must be FDA-approved or recommended by NCCN
inv-25: Initial Therapy — initial dosing regimen for treatment of MM per product labeling.
Initial dosing regimen for treatment of MM per product labeling:
Follow step‑up schedule to mitigate CRS and neurologic toxicity
Criteria for Continued and Maintenance Therapy
inv-26: Continued therapy — criteria for continued therapy and durations.
Criteria for continued therapy and durations
Approval durations: Medicaid/HIM/ICHRA 12 months; Commercial 6 months or to member renewal date
inv-27: Maintenance Therapy — maintenance/continuation dosing rules per labeling.
Maintenance/continuation dosing rules per labeling:
Maintenance dosing adjustment described in product information
Coding, Quantity, and Measurable Criteria
| J9601 | Injection, linvoseltamab-gcpt, 1 mg |
Provider Actions, Prior Authorization & Documentation
Prior authorization — document diagnosis, prior therapies, and dosing
Prior authorization is required. The provider must demonstrate medical necessity by submitting documentation showing diagnosis of multiple myeloma, prior therapies received (including ≥4 prior lines with at least one proteasome inhibitor, one immunomodulatory agent, and one anti‑CD38 monoclonal antibody), and that the requested dosing follows the policy limits or is supported by practice guidelines or peer‑reviewed literature.
- Document prior lines of therapy and intolerances (see Appendix B examples).
- Confirm dose meets step‑up and maintenance schedule (Day 1: 5 mg; Day 8: 25 mg; Day 15: 200 mg; weekly Weeks 4–13; 200 mg every 2 weeks Week 14 onward) or provide supporting literature for off‑label dosing.
Prior authorization and HCPCS billing (J9601)
Bill linvoseltamab‑gcpt using HCPCS code J9601 (Injection, linvoseltamab‑gcpt, 1 mg) and follow the Health Plan’s prior authorization process for specialty oncology drugs.
- Confirm coding guidance prior to claim submission; codes in policy are informational and do not guarantee coverage.
- Follow plan administrative prior authorization procedures for specialty drugs.
Therapeutic alternatives — see Appendix B (may require PA)
Therapeutic alternatives are listed in Appendix B and may be considered preferred prior therapies; providers should review Appendix B and obtain prior authorization for alternative regimens when required by plan policy.
- Appendix B lists multiple alternative regimens that may not be formulary for all lines of business and may require prior authorization.
- Provider must document treatment history and rationale if selecting an alternative prior therapy.
Therapeutic alternatives — pomalidomide regimens and isatuximab combos
Appendix B specifically includes pomalidomide‑containing regimens and isatuximab (Sarclisa) combinations as listed therapeutic alternatives to linvoseltamab‑gcpt.
- Examples include pomalidomide/dexamethasone, pomalidomide/bortezomib/dexamethasone, and Sarclisa® (isatuximab) plus pomalidomide/dexamethasone combinations as shown in Appendix B.
Required documentation — submit office notes and lab results
Providers must submit supporting clinical documentation (office chart notes, laboratory results, or other clinical information) to demonstrate the member meets all approval criteria when requesting authorization.
- Include recent measurable disease data or IMWG progression documentation, prior therapy details, and any supportive evidence for off‑label dosing if applicable.
Required documentation and coding reference — see Prescriber Info/FDA label and J9601
Refer to the Lynozyfic Prescriber Information and FDA label for dosing and safety details and use HCPCS J9601 for billing of linvoseltamab‑gcpt; confirm coding guidance prior to claim submission.
- Prescriber Information and the FDA label are listed as references for dosing and safety.
- HCPCS J9601 is the policy’s billing reference for linvoseltamab‑gcpt (1 mg).
Documentation requirement — missing documentation may lead to denial
Failure to submit the required clinical documentation (office chart notes, lab results, or other clinical information) supporting that the member meets all approval criteria may result in denial of the prior authorization request.
- Ensure all requested supporting records are included with the PA submission to avoid processing delays or denial.
Coding-related denial risk — codes are informational and not a coverage guarantee
Inclusion or exclusion of codes in this policy is informational and does not guarantee coverage; providers must reference current professional coding guidance and the Health Plan’s benefit language before submitting claims.
- Codes listed (e.g., J9601) are for reference only; confirm coding and coverage with plan documents prior to claim submission.
Therapeutic Alternatives and Step Therapy
| Therapeutic alternative | Typical regimen / notes |
|---|---|
| bortezomib / lenalidomide (Revlimid) / dexamethasone | |
| Dosing regimen: varies by regimen and line of therapy; listed in Appendix B as a preferred alternative and may require prior authorization | |
| bortezomib / cyclophosphamide / dexamethasone | |
| Dosing regimen: varies; included in Appendix B as an alternative | |
| bortezomib / doxorubicin (or liposomal doxorubicin) / dexamethasone | |
| Dosing regimen: varies; listed in Appendix B | |
| carfilzomib (Kyprolis) / lenalidomide (Revlimid) / dexamethasone | |
| Dosing regimen: varies; included in Appendix B | |
| ixazomib (Ninlaro) / lenalidomide (Revlimid) / dexamethasone | |
| Dosing regimen: varies; listed as a potential alternative in Appendix B | |
| pomalidomide-containing regimens (e.g., pomalidomide / cyclophosphamide / dexamethasone; pomalidomide / dexamethasone; pomalidomide / bortezomib / dexamethasone) | |
| Dosing regimen: varies; multiple pomalidomide-based combinations are listed in Appendix B as therapeutic alternatives | |
| daratumumab (Darzalex or Darzalex Faspro)–containing regimens (with bortezomib/dexamethasone or with lenalidomide/dexamethasone or with pomalidomide/dexamethasone) | |
| Dosing regimen: varies; Darzalex combinations are included in Appendix B | |
| isatuximab (Sarclisa)–containing regimens (e.g., isatuximab / pomalidomide / dexamethasone; isatuximab / carfilzomib / dexamethasone) | |
| Dosing regimen: varies; isatuximab combinations are listed in Appendix B as alternatives | |
| elotuzumab (Empliciti)–containing regimens | |
| Dosing regimen: varies; included in Appendix B as alternative options | |
| Various multi-agent or intensive regimens (e.g., VTD-PACE, bendamustine-containing combinations, cyclophosphamide / lenalidomide / dexamethasone) | |
| Dosing regimen: varies; Appendix B lists multiple preferred alternative regimens and notes that dosing and maximum doses vary |
| Therapeutic alternative | Typical regimen / notes |
|---|---|
| pomalidomide / cyclophosphamide / dexamethasone | |
| Dosing regimen: varies; listed in Appendix B as a pomalidomide-containing therapeutic alternative | |
| pomalidomide / dexamethasone | |
| Dosing regimen: varies; included in Appendix B | |
| pomalidomide / bortezomib / dexamethasone | |
| Dosing regimen: varies; listed in Appendix B | |
| pomalidomide / carfilzomib (Kyprolis) / dexamethasone | |
| Dosing regimen: varies; included among pomalidomide-containing alternatives in Appendix B | |
| isatuximab (Sarclisa) / pomalidomide / dexamethasone | |
| Dosing regimen: varies; isatuximab plus pomalidomide combinations are specifically listed in Appendix B as alternatives | |
| isatuximab (Sarclisa) / carfilzomib / dexamethasone | |
| Dosing regimen: varies; listed in Appendix B as an isatuximab-containing alternative |
Site of Care and Infusion Requirements
Approval durations set by line of business; site of care not restricted here
The policy specifies approval durations by line of business (for example, Medicaid/HIM/ICHRA and commercial) but does not restrict the site of care in this section.
- Approval durations differ by line of business (see policy approval duration tables).
Infusion administration and monitoring for CRS/neurologic toxicity
Administer linvoseltamab‑gcpt via intravenous infusion following the step‑up dosing schedule and provide appropriate monitoring for cytokine release syndrome (CRS) and neurologic toxicity, ensuring the infusion setting can manage these adverse events.
- Step‑up dosing: Day 1: 5 mg IV; Day 8: 25 mg IV; Day 15: 200 mg IV, then weekly and biweekly maintenance per labeling.
- Monitor for CRS and immune effector cell‑associated neurotoxicity syndrome per boxed warnings.
Definitions and Abbreviations
Background — Product and Regulatory Context
Linvoseltamab‑gcpt (Lynozyfic) is a BCMA‑directed bispecific CD3 T‑cell engager approved under accelerated approval for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy that include a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. Continued approval may be contingent on confirmatory trials. The product is administered by intravenous step‑up dosing and carries boxed warnings for cytokine release syndrome and neurologic toxicity; providers should reference the Lynozyfic Prescriber Information and the HCPCS billing guidance (e.g., J9601) when ordering and billing.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.